IQE (OTCMKTS:IQEPF) & H. Lundbeck A/S (OTCMKTS:HLUYY) Financial Review

IQE (OTCMKTS:IQEPF) and H. Lundbeck A/S (OTCMKTS:HLUYY) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IQE and H. Lundbeck A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQE	0	0	1	0	3.00
H. Lundbeck A/S	1	1	0	0	1.50

Volatility & Risk

IQE has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, H. Lundbeck A/S has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Earnings and Valuation

This table compares IQE and H. Lundbeck A/S’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQE	$207.17 million	1.52	-$92.20 million	N/A	N/A
H. Lundbeck A/S	$2.59 billion	8.45	$209.69 million	$0.88	25.00

H. Lundbeck A/S has higher revenue and earnings than IQE.

Profitability

This table compares IQE and H. Lundbeck A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IQE	N/A	N/A	N/A
H. Lundbeck A/S	6.74%	13.74%	7.16%

Summary

H. Lundbeck A/S beats IQE on 6 of the 9 factors compared between the two stocks.

About IQE

IQE plc, together with its subsidiaries, develops, manufactures, and sells advanced semiconductor materials. It operates through three segments: Wireless, Photonics, and CMOS++. The company manufactures and sells compound semiconductor materials for the wireless market which includes radio frequency devices for wireless communications, and photonics market, that includes applications that transmit and sense visible and infrared lights, as well as advanced semiconductor materials related to silicon. It operates in the United States, rest of the Americas, France, Germany, Israel, the United Kingdom, rest of Europe, the Middle East, Africa, the People's Republic of China, Japan, Taiwan, and rest of the Asia-Pacific. The company was founded in 1988 and is headquartered in Cardiff, the United Kingdom.

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.